News & Events

ABT-263 and Neurodegeneration

A team at Toronto’s Hospital for Sick Children demonstrated that pharmacological ablation of senescent cells using Navitoclax (ABT-263, Focus Cat#10-3141) caused a rapid increase in neural

READ MORE

REV-ERB agonists and Cancer

Researchers at the Salk Institute, the University of California, and the University of Texas have identified a potential new class of cancer therapeutics. REV-ERBs are nuclear hormone

READ MORE